India's Sun Pharma to Acquire US Firm Organon in $11.75 Billion Deal

goodinfo.net — Mon, 27 Apr 2026 11:40:00 +0800

Sun Pharma Announces $11.75 Billion Acquisition of US Drugmaker Organon

On April 27, 2026, India’s largest pharmaceutical company, Sun Pharmaceutical Industries, announced it will acquire US-based Organon & Co. for $11.75 billion. The deal marks one of the largest overseas acquisitions in Indian pharmaceutical history.

Deal Details

Under the agreement, Sun Pharma will acquire Organon through a combination of cash and stock. Upon completion, Organon will become a wholly-owned subsidiary of Sun Pharma, integrating its product pipelines across the US, Europe, and emerging markets.

Organon specializes in women’s health, biosimilars, and established brand medicines, with an extensive global sales network and R&D capabilities. The acquisition will significantly strengthen Sun Pharma’s presence in specialty pharmaceuticals.

Strategic Significance

Analysts note that the deal reflects the accelerating global expansion strategy of Indian pharmaceutical companies. Through this acquisition, Sun Pharma will gain Organon’s mature distribution channels in North America and Europe, while expanding its product portfolio in the high-growth women’s health sector.

“This is not just a breakthrough in terms of deal size — it’s a landmark moment for Indian pharma companies transitioning from generics to specialty drugs.” — Industry analyst

Market Response

Following the announcement, Sun Pharma shares surged on the Bombay Stock Exchange, with investors responding positively to the strategic move. Organon shares also climbed significantly in pre-market trading.

The transaction is expected to close in the second half of 2026, pending regulatory approval from authorities in the US, India, and other relevant jurisdictions.

Sources: CNBC

Pharma on goodinfo.net Daily

India's Sun Pharma to Acquire US Firm Organon in $11.75 Billion Deal

Sun Pharma Announces $11.75 Billion Acquisition of US Drugmaker Organon

Deal Details

Strategic Significance

Market Response